@article{595ec7e7aa884ae99d92f0afa114c1ed,
title = "Obesity predicts persistence of resistant hypertension after surgery in patients with primary aldosteronism",
abstract = "Objective: Primary aldosteronism (PA) is considered a major cause of resistant hypertension (RHT). The prevalence of RHT has been recently reported to reach 18% in general hypertension. However, little is known about the prevalence and the outcomes after adrenalectomy of RHT in PA. Therefore, we aimed to clarify the prevalence and surgical outcomes in patients with both PA and RHT. Patients and Design: Among 550 patients who underwent adrenalectomy for unilateral PA in the Japan PA Study, RHT was defined as an uncontrolled blood pressure (≥140/90 mm Hg) despite treatment with at least any three antihypertensives or hypertension controlled with at least four drugs. Surgical outcome was assessed by the biochemical and clinical outcome. Results: Although 40 (7.3%) patients fulfilled the criteria for preoperative RHT, this should be underestimated because only 36% of patients with postoperative RHT were classified as having preoperative RHT. The prevalence of preoperative RHT was approximately 20% when estimated using the total number of patients with postoperative RHT and the ratio of postoperative RHT in patients with preoperative RHT. Although an improvement in hypertension was achieved in approximately 80% of patients with preoperative RHT, 20% of these exhibited persistent RHT. These patients were more obese than those for whom RHT improved after surgery. Notably, body mass index of ≥25 kg/m2 was an independent predictor of postoperative RHT. Conclusions: The prevalence of RHT in PA was lower than expected even with the adjustment for underestimation. Furthermore, obesity is an independent factor predicting the postoperative persistence of RHT.",
keywords = "adrenalectomy, obesity, primary aldosteronism, resistant hypertension",
author = "Ryo Nakamaru and Koichi Yamamoto and Hiromi Rakugi and Hiroshi Akasaka and Isao Kurihara and Takamasa Ichijo and Yoshiyu Takeda and Takuyuki Katabami and Mika Tsuiki and Norio Wada and Yoshihiro Ogawa and Junji Kawashima and Masakatsu Sone and Takanobu Yoshimoto and Ryuji Okamoto and Megumi Fujita and Hiroki Kobayashi and Kouichi Tamura and Kohei Kamemura and Shintaro Okamura and Miki Kakutani and Akiyo Tanabe and Mitsuhide Naruse",
note = "Funding Information: This study was supported in part by grants‐in‐aid for the Japan Primary Aldosteronism Study and the Japan Rare Adrenal Diseases Study from the Practical Research Project for Rare/Intractable Diseases from the Japan Agency for Medical Research and Development (AMED) (JP17ek0109122, JP18ek0109352 and JP19ek0109352) and grants from the National Center for Global Health and Medicine, Japan (27‐1402, 30‐1008). Funding Information: This study was supported in part by grants-in-aid for the Japan Primary Aldosteronism Study and the Japan Rare Adrenal Diseases Study from the Practical Research Project for Rare/Intractable Diseases from the Japan Agency for Medical Research and Development (AMED) (JP17ek0109122, JP18ek0109352 and JP19ek0109352) and grants from the National Center for Global Health and Medicine, Japan (27-1402, 30-1008). We wish to thank all of the healthcare professionals who dedicated their expertise to the care of patients described in the present report. Publisher Copyright: {\textcopyright} 2020 John Wiley & Sons Ltd",
year = "2020",
month = sep,
day = "1",
doi = "10.1111/cen.14203",
language = "English",
volume = "93",
pages = "229--237",
journal = "Clinical Endocrinology",
issn = "0300-0664",
publisher = "Wiley-Blackwell",
number = "3",
}